Vaccine for the prevention of breast cancer relapse
The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
1. A method of inducing protective or therapeutic immunity against a HER2/neu expressing tumor with a fluorescence in situ hybridization (FISH) rating of greater than about 0 to less than about 2.0 for HER2/neu gene expression in a subject, the method comprising administering to the subject an effective amount of a composition comprising a pharmaceutically effective carrier, a peptide having the amino acid sequence SEQ ID NO:2, and an adjuvant comprising a compound or compounds selected from the group consisting of emulsifiers, muramyl dipeptides, avridine, aluminum hydroxide, chitosan-based adjuvants, saponins, oils, Amphigen, LPS, bacterial cell wall extracts, bacterial DNA, CpG sequences, synthetic oligonucleotides, cytokines and combinations thereof.
2. The method of claim 1 , further comprising administering to the subject a booster composition comprising an effective amount of a pharmaceutically effective carrier and a peptide having the amino acid sequence SEQ ID NO:2.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the HER2/neu expressing tumor has an immunohistochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression.
5. The method of claim 2 , wherein the booster composition further comprises an adjuvant.
6. The method of claim 3 , wherein the human had node positive breast cancer.
7. The method of claim 3 , wherein the human had node negative breast cancer.
8. The method of claim 5 , wherein the adjuvant comprising a compound or compounds is selected from the group consisting of emulsifiers, muramyl dipeptides, avridine, aluminum hydroxide, chitosan-based adjuvants, saponins, oils, Amphigen, LPS, bacterial cell wall extracts, bacterial DNA, CpG sequences, synthetic oligonucleotides, cytokines and combinations thereof.
9. The method of claim 5 , wherein the adjuvant comprises granulocyte macrophage-colony stimulating factor (GM-CSF).